As a result, to treat pancreatic cancer, CAR is engineered to recognize mesothelin (membrane protein antigen) which is overexpressed in pancreatic cancer and other common solid tumors (Fig. 2) but is not expressed on T cells [118, 119] Mesothelin is an attractive target for immunotherapy due to its limited expression in normal tissues, its overexpression in malignant tissues, and its high immunogenicity [120]. The gene discussed is MSLN; the disease is pancreatic neoplasm.